Less than 10% of people who could benefit from GLP-1 drugs like Wegovy have access to them, caution the World Health Organization as it issues its inaugural advice on the drugs.
With more than one billion individuals worldwide now living with obesity, it is advocating for increased and just access to this class of drugs.
Per forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"Our new guidelines recognises that excess weight is a long-term condition that can be treated with thorough and lifelong support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are major barriers to universal availability to the treatments that can help people shift significant weight, explains the body.
Skinny Jab Scarcity
Despite the present most favorable outlook, the production of these medications could only cover approximately 100 million people – under 10% of those who need them, according to the health organization.
The advice urges countries and companies to widen access, by strategies like patent sharing.
Exclusive production rights on semaglutide – the main component of a leading brand – is scheduled to end in multiple countries in 2026.
How Obesity Injections Operate
The injections mimick a natural hormone to slow digestion, curb appetite and enhance the sense of being full so individuals consume fewer calories.
Patients commonly start to lose weight in the initial weeks of commencing the once-weekly jabs.
Evidence points to users may regain a significant portion a year later of stopping the drug, because their normal hunger come back.
To be carrying excess weight elevates your likelihood for contracting medical conditions, like diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight affects individuals in countries worldwide and was responsible for millions of fatalities worldwide in 2024, as per the WHO.
